[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psychedelic-experiences\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psychedelic-experiences":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,126,155,182,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100620644","phase-1-consciousness-and-psilocybin-effects-on-well-being-the-copewell-study-100620644",false,"NCT07360301","Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","Inclusion Criteria:\n\n* Age 18 to 45 years (inclusive) at screening, of any identified gender and racial\u002Fethnic group\n* Physically healthy; does not meet criteria for an exclusionary medical condition\n* No exclusionary sleep condition\n* English-speaking (able to provide consent and complete questionnaires)\n* Sub-optimal self-reported wellbeing\n\nExclusion Criteria:\n\n* Exclusionary DSM-5 psychiatric diagnosis and\u002For active suicidal ideation\n* Exclusionary medical conditions or sleep conditions\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Clinically significant electrocardiogram (ECG)\n* Use of psychotropic or CNS-altering medications within 3 months of screening\n* Hypertension or tachycardia",true,"ALL","18 Years","45 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the \"trip\") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.",[27,28],"Well-Being, Psychological","Psychedelic Experiences","NOT_YET_RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":21},"2026-09",{"date":37,"type":21},"2028-02",{"name":39,"class":40},"University of Wisconsin, Madison","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":101,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":41},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.","17 Years","99 Years",{"count":53,"type":21},1000000,[55],"NA","BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,28,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[102,103,104,105,106,107,108,109,110,111,112,113,114,115,116],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","2026-06-16",{"date":119,"type":33},"2026-06-22",{"date":121,"type":21},"2026-08-01",{"date":123,"type":21},"2028-12-31",{"name":125,"class":40},"Veterans Recovery Network Inc.",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":41},"100505829","phase-1-the-enhance-study-tavns-and-psilocybin-100505829","NCT05866471","The ENHANCE Study: taVNS and Psilocybin","Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin","ENHANCE","Inclusion Criteria:\n\n* English speaking\n* Ability\u002Fwillingness to complete all study activities\n* Modest reduction in emotional well-being\n* Medically healthy (does not meet criteria for an exclusionary medical condition)\n* Blood pressure and heart rate within established ranges at screening\n* Use of acceptable contraceptive methods (sexually active males and women of childbearing potential)\n\nExclusion Criteria:\n\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Current or clinically significant psychiatric disorder that, in the investigator's judgment, would interfere with participation or increase risk\n* Current use of drugs or medications, prescribed or otherwise, that may interact with psilocybin\n* Use of investigational drugs, biologics, or devices within 30 days of enrollment\n* Use of psychedelic or related agents within three months of Dosing Day\n* Clinically significant electrocardiogram (ECG)\n* Vitals outside acceptable range\n* Pregnancy and currently breastfeeding\n* Unwillingness to go without tobacco products for 12 hours or more\n* Inability to undergo fMRI scanning\n* Recent ear trauma, hearing loss (if clinically significant), or deafness\n* Family history of a psychotic disorder in a first degree relative","70 Years",{"count":136,"type":21},108,[24],"This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS or no VNS.",[140,28,141],"Healthy","Vagus Nerve Stimulation",[143,144,141,145],"Psilocybin","Psychedelics","Healthy Volunteer","RECRUITING","2026-03-31",{"date":149,"type":33},"2026-04-03",{"date":151,"type":33},"2025-01-27",{"date":153,"type":21},"2028-01",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":163,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100587337","antidepressant-response-of-dmt-masked-with-propofol-100587337","NCT06927076","Antidepressant Response of DMT Masked With Propofol","Investigating the Role of the Psychedelic Experience in the Antidepressant Response in Patients With Major Depression: a Placebo-controlled Factorial Trial With DMT Masked With Propofol (DMT4D-Study)","DMT4D","Inclusion Criteria:\n\n1. Participants must meet DSM-5 criteria for MDD of at least moderate severity (MADRS≥20).\n2. Participants either currently do not use antidepressants or are treated with a stable dose for at least 4 weeks prior to randomization.\n3. Age ≥ 21 years old.\n4. Sufficient understanding of the German language.\n5. Able to understand the study procedures and risks and willing to adhere to the protocol and sign the consent form.\n6. Willing not to drive or operate heavy machinery on the treatment day.\n7. Willing to refrain from more than 7 standard alcoholic drinks a week, more than 10 cigarettes a day, more than 2 cups of coffee a day, and any illicit substances during study participation.\n8. Willing to use effective contraceptive measures throughout study participation.\n\nExclusion Criteria:\n\n1. Past or present bipolar or psychotic disorder, including depressive disorder with psychotic features.\n2. First-degree relative with a psychotic or bipolar disorder.\n3. Significant prodromal psychotic symptoms (Prodromal Questionnaire-16 symptoms ≥ 6).\n4. Psychiatric condition judged to be incompatible with establishment of rapport with study team members and\u002For safe exposure to DMT, e.g. diagnosed or suspected borderline personality disorder.\n5. Current post-traumatic stress disorder or acute stress reaction due to a traumatic event.\n6. Post-partum depression.\n7. Pregnant or breastfeeding women.\n8. Current or recent history of significant suicide ideation or suicide behavior within the past 6 months.\n9. Current severe substance use disorder other than nicotine.\n10. Planned ketamine, other psychedelic, or electroconvulsive treatment or any such treatment within the past 3 months.\n11. Any lifetime use of DMT, use of any other psychedelics within last 3 month or lifetime use of any other psychedelics more than 15 times.\n12. Patients who are treated with neuroleptics or known antagonists of 5-HT2 receptors or monoamine oxidase inhibitors (MAOI) and are not able\u002Fwilling to pause.\n13. Increased risk for adverse reactions to propofol or soja products.\n14. Increased risk for aspiration.\n15. Increased risk for difficult mask ventilation.","21 Years",{"count":165,"type":21},112,[55],"The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.",[169,28],"Major Depressive Disorder",[171,172],"N,N-dimethyltryptamine (DMT)","neuroplasticity","2026-03-27",{"date":175,"type":33},"2026-04-02",{"date":177,"type":33},"2025-08-05",{"date":179,"type":21},"2029-03",{"name":181,"class":40},"University Hospital, Basel, Switzerland",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":15,"sex":16,"minAge":163,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":41},"100550679","phase-1-safety-for-home-administration-of-microdose-psilocybin-use-100550679","NCT06450210","Safety for Home Administration of Microdose Psilocybin Use","Inclusion Criteria:\n\n* 21 to 60 years old\n* Have given written informed consent\n* Have at least a high-school level of education or equivalent (e.g. GED) and be fluent in English\n* Be healthy and psychologically stable as determined by screening for medical and psychiatric problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests\n* Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, within 24 hours of each drug administration. The exception is caffeine.\n* Agree not to take any as needed (PRN) medications on the mornings of drug sessions\n* Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration.\n* Agree that for one week before each drug session, he\u002Fshe will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.\n* Licensed to drive (for driving simulator test).\n\nExclusion Criteria:\n\n* Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing; women who are of child-bearing potential and sexually active who are not practicing an effective means of birth control.\n* Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g. atrial fibrillation, corrected QT interval (QTc) \\> 450 msec), artificial heart valve, or transient ischemic attack (TIA) in the past year\n* Epilepsy\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Currently taking psychoactive drugs (prescribed or not) on a daily basis. This includes nicotine but excepts caffeine.\n* Currently taking on a regular (e.g. daily) basis any medications having a centrally-acting serotonergic effect, including monoamine oxidase inhibitors (MAOIs). For individuals who have intermittent or PRN use of such medications, psilocybin sessions will not be conducted until at least five half-lives of the agent have elapsed after the last dose.\n* More than 20% outside the upper or lower range of ideal body weight according to Metropolitan Life height and weight table\n* History of schizophrenia spectrum disorder\n* History of bipolar I disorder\n* History of substance induced psychotic disorder\n* Current history of meeting Diagnostic and Statistical Manual (DSM)-5 criteria for a moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine)\n* Have a first degree relative with bipolar I disorder, or schizophrenia spectrum disorder.\n\nCardiovascular screening: To qualify for the study, blood pressure at screening will be less than 130 mmHg systolic, 80 mmHg diastolic, and 90 beats per minute; mean heart rate must also be no less than 40 beats per minute. Blood pressure will be taken while subjects are at rest and have been seated or supine for at least 5 minutes.","60 Years",{"count":190,"type":21},20,[24],"The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants.\n\nEligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.",[28],"2026-02-19",{"date":196,"type":33},"2026-02-23",{"date":198,"type":33},"2024-12-06",{"date":200,"type":21},"2027-07",{"name":202,"class":40},"Johns Hopkins University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":15,"sex":16,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100556809","the-effects-of-psilocybin-on-shared-experience-in-film-processing-100556809","NCT06529939","The Effects of Psilocybin on Shared Experience in Film Processing","Inclusion Criteria:\n\nParticipants must:\n\n* Have access to an internet connection\n* Be in good general health\n* Be 19 years of age, or older\n* Be willing to follow the study protocol\n\nExclusion Criteria:\n\nThe following people will be excluded from the study. Those who:\n\n* Are unable to read English\n* Have high blood pressure\n* Are pregnant (determined by a urine pregnancy test at in-person screening)\n* Are not using effective methods of contraception with their partner(s) (e.g. oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine coil, intrauterine device, tubal ligation, or barrier method)\n* Are taking chronic administration of tricyclic antidepressants and\u002For lithium\n* Are taking acute administration of serotonin reuptake inhibitors\n* Are currently using the antipsychotic medication haloperidol\n* Are currently using monoamine oxidase inhibitors\n* Have any current or past history of meeting the Diagnostic and Statistical Manual of Mental Illnesses (DSM-V) criteria for schizophrenia, bipolar I, bipolar II, or psychotic symptoms\n* Have any first or second-degree relatives with history of above disorders\u002Fsymptoms\n* Have any other diagnosed and\u002For extreme psychiatric disorders, such as anxiety, depression, post-traumatic stress disorder (PTSD), addiction, obsessive-compulsive disorder (OCD), etc.\n* Have any history of suicidal behaviour or current\u002Frecent suicidal ideation (determined by the Columbia-Suicide Severity Rating Scale \\[C-SSRS\\] at in-person screening)","19 Years",{"count":211,"type":21},30,[55],"The goal of this clinical trial is to learn whether certain methods of detecting awareness in vegetative or minimally conscious patients (using neuroimaging) are sensitive to the effects of psilocybin (a psychedelic drug). One of these methods includes scanning peoples\\' brains while they watch a film. When different individuals watch a film, their brains become synchronized with each other as they watch the plot unfold. Most importantly, if a seemingly unconscious patient also shows the same brain-synchronization, it means they might actually be conscious and aware.\n\nTo approach this goal, the investigators will be carrying out this trial in healthy volunteers. This will help better understand whether psilocybin may be a potential treatment for restoring awareness in these patients. The main questions it aims to answer are:\n\n* Does psilocybin enhance or diminish brain synchrony during a film?\n* Do changes in brain synchrony reflect differences in each individual\\'s conscious experience?\n\nParticipants will be asked to:\n\n* Attend two brain scanning sessions and watch a series of film clips, perform a brief mental imagery task, and listen to music - once under a placebo, and once under psilocybin.\n* Play a series of games that assess their cognition (memory, reasoning, planning, etc.).\n* Perform a series of visual illusions tasks.",[215,28],"Disorders of Consciousness",[143,217,218,215,219,220],"Functional Magnetic Resonance Imaging (fMRI)","Cognition","Film Processing","Healthy Volunteers","2024-09-24",{"date":223,"type":33},"2024-09-27",{"date":225,"type":21},"2024-11",{"date":227,"type":21},"2025-09",{"name":229,"class":40},"Western University, Canada"]